Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = nirmaltrelvir/ritonavir

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
15 pages, 2374 KiB  
Article
Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
by Cosmo Del Borgo, Silvia Garattini, Carolina Bortignon, Anna Carraro, Daniela Di Trento, Andrea Gasperin, Alessandra Grimaldi, Sara Giovanna De Maria, Sara Corazza, Tiziana Tieghi, Valeria Belvisi, Blerta Kertusha, Margherita De Masi, Ombretta D’Onofrio, Gabriele Bagaglini, Gabriella Bonanni, Paola Zuccalà, Paolo Fabietti, Eeva Tortellini, Mariasilvia Guardiani, Alessandra Spagnoli, Raffaella Marocco, Danilo Alunni Fegatelli, Miriam Lichtner and LATINA COVID-groupadd Show full author list remove Hide full author list
Viruses 2023, 15(4), 1025; https://doi.org/10.3390/v15041025 - 21 Apr 2023
Cited by 13 | Viewed by 4064
Abstract
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability in a real-life setting. A single-center observational study was set up, with the [...] Read more.
In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability in a real-life setting. A single-center observational study was set up, with the involvement of 1118 patients, with complete follow-up data, treated between the 5th of January and the 3rd of October 2022 at Santa Maria Goretti’s hospital in Latina, Central Italy. A univariable and a multivariable analysis were performed on clinical and demographic data and composite outcome, the persistence of symptoms at 30 days and time to negativization, respectively. The three antivirals showed a similar effectiveness in containing the progression of the infection to severe COVID-19 and a good tolerability in the absence of serious adverse effects. Persistence of symptoms after 30 days was more common in females than males and less common in patients treated with molnupiravir and nirmatrelvir/r. The availability of different antiviral molecules is a strong tool and, if correctly prescribed, they can have a significant role in changing the natural history of infection for frail persons, in which vaccination could be not sufficient for the prevention of severe COVID-19. Full article
(This article belongs to the Special Issue Efficacy and Safety of Antiviral Therapy)
Show Figures

Figure 1

Back to TopTop